2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Can J Gastroenterol Hepatol. 2020 Nov 30;2020:8825615. doi: 10.1155/2020/8825615. eCollection 2020.
Both nonalcoholic fatty liver disease (NAFLD) and ischemic heart disease have common pathogenic links. Evidence for the association of NAFLD with acute coronary syndromes (ACS), complex multivessel coronary artery disease (CAD), and increased mortality risk in ACS patients is still under investigation. Therefore, we conducted a systematic review aiming to clarify these gaps in evidence.
We conducted a systematic search on PubMed and EMBASE with predefined keywords searching for observational studies published till August 2020. NAFLD diagnosis was accepted if confirmed through biopsy, imaging techniques, surrogate markers, or codes. Full articles that satisfied our inclusion and exclusion criteria were included in the systematic review. We used the NHLBI quality assessment tool to evaluate included studies.
Seventeen observational studies with a total study population of approximately 21 million subjects were included. Eleven studies evaluated whether NAFLD is an independent risk factor for developing ACS with conflicting results, of which eight studies demonstrated a significant association between NAFLD and ACS, mainly in Asian populations, while three reported a lack of an independent association. Conflicting results were reported in studies conducted in Europe and North America. Moreover, a total of five studies evaluated whether NAFLD and fatty liver severity in ACS patients are associated with a complex multivessel CAD disease, where all studies confirmed a significant association. Furthermore, seven out of eight studies evaluating NAFLD and hepatic steatosis severity as a predictor of all-cause and cardiovascular mortality and in-hospital major adverse cardiovascular events (MACE) in ACS patients demonstrated a significant independent association.
NAFLD patients are associated with an independently increased risk of developing ACS, mainly in Asian populations, with inconsistent results in North American and European individuals. Moreover, NAFLD and hepatic steatosis severity were both independently correlated with complex multivessel CAD, mortality, and in-hospital MACE in ACS patients.
非酒精性脂肪性肝病(NAFLD)和缺血性心脏病具有共同的发病机制。NAFLD 与急性冠状动脉综合征(ACS)、复杂多血管冠状动脉疾病(CAD)以及 ACS 患者死亡风险增加之间的关联证据仍在研究中。因此,我们进行了一项系统评价,旨在阐明这些证据中的空白。
我们在 PubMed 和 EMBASE 上进行了系统搜索,使用预设的关键词搜索截至 2020 年 8 月发表的观察性研究。如果通过活检、影像学技术、替代标志物或代码确认 NAFLD 诊断,则接受 NAFLD 诊断。符合纳入和排除标准的全文均纳入系统评价。我们使用 NHLBI 质量评估工具评估纳入的研究。
共纳入 17 项观察性研究,总计约 2100 万例研究对象。11 项研究评估了 NAFLD 是否是 ACS 发生的独立危险因素,结果存在争议,其中 8 项研究表明 NAFLD 与 ACS 之间存在显著关联,主要见于亚洲人群,而 3 项研究报告两者之间无独立关联。欧洲和北美的研究结果存在争议。此外,共有 5 项研究评估了 ACS 患者的 NAFLD 和脂肪肝严重程度与复杂多血管 CAD 疾病之间的关系,所有研究均证实了两者之间存在显著关联。此外,在评估 NAFLD 和肝脂肪变性严重程度作为 ACS 患者全因和心血管死亡率以及住院期间主要不良心血管事件(MACE)预测指标的 8 项研究中的 7 项研究中,均显示出显著的独立相关性。
NAFLD 患者发生 ACS 的风险独立增加,主要见于亚洲人群,而北美和欧洲人群的结果存在差异。此外,NAFLD 和肝脂肪变性严重程度与 ACS 患者的复杂多血管 CAD、死亡率和住院期间 MACE 均独立相关。